Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Lack of evidence from HPLC P-32-post-labelling for tamoxifen-DNA adducts in the human endometrium
Autore:
Carmichael, PL; Sardar, S; Crooks, N; Neven, P; Van Hoof, I; Ugwumadu, A; Bourne, T; Tomas, E; Hellberg, P; Hewer, AJ; Phillips, DH;
Indirizzi:
UnivnLondon Imperial Coll Sci Technol & Med, Sch Med, Div Biomed Sci, Londo Univ London Imperial Coll Sci Technol & Med London England SW7 2AZ Londo Klin St Jan, B-1000 Brussels, Belgium Klin St Jan Brussels Belgium B-1000 lin St Jan, B-1000 Brussels, Belgium Univ London St Georges Hosp, London SW17 0QT, England Univ London St Georges Hosp London England SW17 0QT on SW17 0QT, England Oulu Univ Hosp, Oulu 90220, Finland Oulu Univ Hosp Oulu Finland 90220Oulu Univ Hosp, Oulu 90220, Finland Gothenburg Univ, Sahlgrens Hosp, S-41345 Gothenburg, Sweden Gothenburg Univ Gothenburg Sweden S-41345 sp, S-41345 Gothenburg, Sweden Inst Canc Res, Haddow Labs, Sutton SM2 5NG, Surrey, England Inst Canc ResSutton Surrey England SM2 5NG tton SM2 5NG, Surrey, England
Titolo Testata:
CARCINOGENESIS
fascicolo: 2, volume: 20, anno: 1999,
pagine: 339 - 342
SICI:
0143-3334(199902)20:2<339:LOEFHP>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
BREAST-CANCER PATIENTS; ADJUVANT TAMOXIFEN; RAT; SAMPLES;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Carmichael, PL UnivnLondon Imperial Coll Sci Technol & Med, Sch Med, Div Biomed Sci, Londo Univ London Imperial Coll Sci Technol & Med London England SW7 2AZ
Citazione:
P.L. Carmichael et al., "Lack of evidence from HPLC P-32-post-labelling for tamoxifen-DNA adducts in the human endometrium", CARCINOGENE, 20(2), 1999, pp. 339-342

Abstract

Tamoxifen is associated with an increased incidence of endometrial cancer in women. It is also a potent carcinogen in rat liver and forms covalent DNA adducts in this tissue. A previous study exploring DNA adducts in human endometria, utilizing thin layer chromatography P-32-post-labelling, found no evidence for adducts in tamoxifen-treated women [Carmichael,P.L., Ugwumadu,A.H.N., Neven,P., Hewer,A,J,, Poon,G,K, and Phillips,D.H. (1996) Cancel Res., 56, 1475-1479]. However, subsequent work utilizing HPLC P-32-post-labelling [Hemminki,K., Ranjaniemi,H., Lindahl,B, and Moberger,B, (1996) CancerRes., 56, 4374-4377] suggested that very low levels could be detected. We have sought to investigate this question further by reproducing the HPLC methodology at two centres, and analysing endometrial DNA from 20 patients treated with 20 mg/day tamoxifen for between 22 and 65 months. Liver DNA isolated from tamoxifen-treated rats was used as a positive control. We found no convincing evidence for tamoxifen-derived DNA adducts in human endometrium, HPLC elution profiles of post-labelled DNA from tamoxifen-treated women were indistinguishable from those obtained with DNA from 14 untreated womenand from six women taking toremifene, an analogue of tamoxifen.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/11/20 alle ore 04:27:58